EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies

CHMP Rejection Of Herceptin Biosimilar And Suspension Of Generics To Be Reviewed

 
• By Dave Wallace
  
EMA
The EMA will review a pair of CHMP decisions following re-examination requests

More from Biosimilars

More from Products